# Tango Therapeutics (stock symbol: TNGX) Logo in transparent PNG format

## Tango Therapeutics Logo large

### Tango Therapeutics Logo large Download PNG (16.47 KB)

![Tango Therapeutics Logo large Download PNG (16.47 KB)](/img/orig/TNGX_BIG-d2f42151.png)

## Tango Therapeutics Logo icon format

### Tango Therapeutics Logo icon format Download PNG (14.04 KB)

![Tango Therapeutics Logo icon format Download PNG (14.04 KB)](/img/orig/TNGX-65694cb5.png)

## About Tango Therapeutics

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.

1. Website domain: tangotx.com
2. Employees: 109
3. Marketcap: $0.29 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
